01:01am Tuesday 21 May 2019

Could cancer anti-sickness drug end the misery for IBS patients?

Could a commonly-prescribed anti-sickness drug be the answer for the 1.3 million people in the UK who suffer the pain and misery of irritable bowel syndrome with diarrhoea (IBS-D)?

A nationwide clinical trial led by researchers at The University of Nottingham and funded by the National Institute for Health Research (NIHR)will assess the medication ondansetron, which is currently used by doctors to help cancer patients cope with the nausea and vomiting associated with chemotherapy, radiotherapy and surgery.

The research will aim to establish whether a much lower dose of the drug could also be a successful treatment for the abdominal pain and urgent bowel movements typically experienced by IBS patients.

The researchers are aiming to recruit 400 adults who have IBS with diarrhoea from more than 20 hospitals across the UK to take part in the research and are appealing for anyone interested in taking part to visit its newly launched website – https://ctru.leeds.ac.uk/triton – to find out whether they are eligible for the study by answering a few simple questions.

Disruptive

Professor Robin Spiller, of the University’s Nottingham Digestive Diseases Centre, said: “Our pilot study suggested this was very valuable for reducing the need for urgent bowel movements which patients find so disruptive of their daily activities, both at work and when they should be relaxing and enjoying life.”

The trial is being carried out in collaboration with Nottingham University NHS Hospital Trust, as part of the NIHR Nottingham Biomedical Research Centre, and will be run from the Leeds Clinical Trials Research Unit at the University of Leeds.

Half of the volunteers taking part in the 12-week study will be prescribed ondansetron, while the other half will receive a placebo.

Participants will be asked to keep a detailed diary and respond to daily text messages to document their symptoms which will help doctors to assess any potential benefits of the new medication.

Ondansetron was developed to treat the side effects of chemotherapy which cause abnormally high amounts of a natural substance called serotonin to be released. This stimulates receptors in the brain and gut and sends signals to the part of the brain that causes nausea and controls vomiting.

The drug ondansetron works by blocking the serotonin and interrupting the messages which trigger nausea and sickness but it also has important effects on the gut.

Safe, cheap and fewer side effects

Some patients with IBS with diarrhoea have an excess of serotonin in their intestine which stimulates frequent bowel movements and the researchers are keen to find out whether the ondansetron can also work to block the action of the serotonin in this instance.

The patient’s response to the drug may also depend on genetic factors so the variation in the gene controlling the production of serotonin will also need to be considered.

If the ondansetron is found to be effective then unlike most new treatments as it is “off patent” it is inexpensive could be easily introduced to both improve treatment for patients and save the NHS money.

Ondansetron has been used as an anti-sickness medication for around 30 years, so doctors are confident that it is safe and is unlikely to have any unexpected side effects.

If it is proved to be successful in treating IBS with diarrhoea, ondansetron could be rapidly adopted and lead to a change in NICE guideline recommendations. This would mean GPs could prescribe a cheap drug to help patients with the condition throughout the UK.

Among those hospitals taking part are: Nottingham City Hospital; St James’ University Hospital, Leeds; Royal Stoke University Hospital; Barts Health NHS Trust, London; St Marks Hospital, London North West; University College London; Wythenshawe Hospital, Manchester; Salford Royal NHS Foundation Trust; Darlington Memorial Hospital, County Durham; City Hospital, Sandwell and West Birmingham; Barnsley Hospital; Western General, Edinburgh; Royal Hallamshire Hospital, Sheffield; The James Cook Hospital, South Tees.

 

— Ends —

Our academics can now be interviewed for broadcast via our Media Hub, which offers a Globelynx fixed camera and ISDN line facilities at University Park campus. For further information please contact a member of the Communications team on +44 (0)115 951 5798, email  pressoffice@nottingham.ac.uk or see the Globelynx website for how to register for this service.

For up to the minute media alerts, follow us on Twitter

Notes to editors: 

The University of Nottingham is a research-intensive university with a proud heritage, consistently ranked among the world’s top 100. Studying at the University of Nottingham is a life-changing experience and we pride ourselves on unlocking the potential of our 44,000 students – Nottingham was named both Sports and International University of the Year in the  2019 Times and Sunday Times Good University Guide, was awarded gold in the TEF 2017and features in the top 20 of all three major UK rankings. We have a pioneering spirit, expressed in the vision of our founder Sir Jesse Boot, which has seen us lead the way in establishing campuses in China and Malaysia – part of a globally connected network of education, research and industrial engagement. We are ranked eighth for research power in the UK according to REF 2014. We have six beacons of research excellence helping to transform lives and change the world; we are also a major employer, proud of our Athena SWAN silver award, and a key industry partner- locally and globally.

 

Story credits

More information is available from Professor Robin Spiller in the School of Medicine, University of Nottingham on +44 (0)115 823 1090, robin.spiller@nottingham.ac.uk

Emma Thorne – Media Relations Manager

 


Share on:
or:

MORE FROM Irritable bowel syndrome

Health news